Ovid Therapeutics (OVID) Income from Continuing Operations (2016 - 2026)

Ovid Therapeutics has reported Income from Continuing Operations for 11 years, with the latest figure at 16988000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 65.98% year-over-year to 16988000.0; the trailing twelve-month figure through Mar 2026 stood at 24167000.0 (up 3.23% YoY), and the FY2025 full-year result was 17414000.0, up 34.12% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 16988000.0, down from 9663000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 9663000.0 in Q4 2025, with the low at 16988000.0 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 9843648.82 across 5 years, with a median of 11967771.0 in 2022.
• The largest YoY upside for Income from Continuing Operations was 204.43% in 2025 against a maximum downside of 154.97% in 2025.
• Ovid Therapeutics' Income from Continuing Operations stood at 11504789.0 in 2022, then sank by 33.18% to 15322000.0 in 2023, then soared by 39.61% to 9253000.0 in 2024, then soared by 204.43% to 9663000.0 in 2025, then slumped by 275.8% to 16988000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 16988000.0 (Q1 2026), 9663000.0 (Q4 2025), and 12158000.0 (Q3 2025), per Business Quant data.